Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in active non-radiographic axial spondyloarthritis
2015-001106-33Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA) (3 arms), sponsored by Novartis. Primary endpoint: ASAS40 response in TNF-naive patients at Week 16. Started Jan 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2015-001106-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001106-33.